July 24, 2024
Canine Atopic Dermatitis Treatment Drugs Market

Rising Adoption Of Biologic Drugs Anticipated To Openup New Avenue For Canine Atopic Dermatitis Treatment Drugs Market

The Canine Atopic Dermatitis Treatment Drugs Market is estimated to be valued at US$ 1038.28 Mn in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Canine atopic dermatitis is a chronic skin condition in dogs that causes intense itching, inflammation and skin lesions. Drugs used for treatment include antihistamines, corticosteroids, omega-3 and 6 fatty acids supplements and biologic drugs. Biologic drugs are gaining popularity due to their targeted approach with lesser side effects. They block certain proteins in the skin that cause inflammation and itching in atopic dogs.

Market Dynamics:
The major drivers fueling growth of the canine atopic dermatitis treatment drugs market include rising pet adoption especially in developed countries and growing awareness about animal health. According to the American Pet Products Association, around 85 million families in the U.S. own a pet. This high pet ownership has increased spending on pet care including treatment of skin allergies and other conditions. Furthermore, biologic drugs for canine atopic dermatitis are witnessing strong demand. These drugs have revolutionized the treatment approach with their selective mode of action to provide longer remission periods and relieve symptoms. However, high costs of biologics compared to other drugs may restrict their adoption in developing regions to some extent during the forecast period.

Segment Analysis
The canine atopic dermatitis treatment drugs market is dominated by antihistamines as the first line of treatment for mild to moderate atopic dermatitis in dogs. Antihistamines help relieve itching by blocking the effects of histamine, which is released during allergic reactions and causes itching. Cyproheptadine and hydroxyzine are among the most commonly prescribed oral antihistamines. However, corticosteroids remain the most effective treatment option for moderate to severe atopic dermatitis cases and account for a sizable portion of the market. Topical and oral corticosteroids are preferred due to their quick relief from itching and skin inflammation.

PEST Analysis
Political: Regulations pertaining to efficacy and safety testing of veterinary drugs are becoming more stringent globally. This could increase the barriers of entry for new market players.
Economic: Rising pet ownership and increasing disposable incomes in emerging nations are fueling market growth. However, higher treatment costs may limit the market among price-sensitive consumers.
Social: Growing humanization of pets is creating demand for advanced treatment options. Pet owners now prefer therapies that improve quality of life for pets without side effects.
Technological: Companies are investing in novel therapies such as targeted monoclonal antibody treatments with fewer side effects than steroids. Biologics hold promise but are currently high priced.

Key Takeaways

Global Canine Atopic Dermatitis Treatment Drugs Market Size  is expected to witness high growth, exhibiting 16% CAGR over the forecast period, due to increasing pet ownership and growing willingness to spend on pet healthcare. The market size is projected to reach US$ 2,309.54 Mn by 2030 from US$ 1038.28 Mn in 2023.

Regional analysis: North America dominates the market currently due to high pet care expenditures and rapid uptake of new therapies. However, Asia Pacific is anticipated to witness the highest growth rate during the forecast period with rising pet care awareness in China and India.

Key players operating in the canine atopic dermatitis treatment drugs market are Zeotis Inc, Elanco Animal Health Incorporated, Virbac, Kindred Biosciences, Inc., Nippon Zenyaku Kogyo Co., Ltd., Bioiberica S.A.U., Dechra Pharmaceuticals Plc, and Toray Industries, Inc. Leading players are focusing on expanding their portfolios through acquisitions and new drug approvals to capitalize on the lucrative market opportunities.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it